REVIEW PAPER
Advances in tumor-infiltrating B lymphocytes
1
College of Basic Medical Science, China Three Gorges University, China
2
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, China
3
Institute of Infection and Inflammation, China Three Gorges University, China
Submission date: 2024-10-13
Final revision date: 2024-11-28
Acceptance date: 2024-12-17
Publication date: 2025-05-20
Cent Eur J Immunol 2025;(2):124-134
KEYWORDS
prognosisimmunotherapyclinical significancetumor-infiltrating B lymphocytetertiary lymphoid structure
ABSTRACT
In the landscape of tumor immunotherapy, T cell-mediated immune responses have consistently captured the attention, while the contributions of B cells have been neglected. Nevertheless, growing evidence underscores the pivotal role of tumor-infiltrating B cells and plasma cells, collectively termed tumor-infiltrating B lymphocytes (TIL-B), in cancer treatment. These cells not only contribute significantly to therapeutic outcomes and prognostication in the realms of standard treatment and immune checkpoint inhibition but also open avenues for novel immunotherapeutic strategies. Interestingly, the heterogeneity within TIL-B populations, marked by diverse phenotypic subgroups, provides them with the capacity to exert both antitumor and protumor influences. Therefore, a comprehensive understanding of TIL-B interactions with tumors would be helpful for harnessing TIL-B as targets in tumor immunotherapy. Here, we survey the current state of TIL-B research with the aim of elucidating their role in tumor immunotherapy and offering insights for the development of TIL-B-based therapeutic approaches.
REFERENCES (60)
1.
Fridman WH, Petitprez F, Meylan M, et al. (2021): B cells and cancer: To B or not to B? J Exp Med 218.
2.
Qian J, Olbrecht S, Boeckx B, et al. (2020): A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res 30: 745-762.
3.
Griss J, Bauer W, Wagner C, et al. (2019): B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun 10: 4186.
4.
Ma J, Wu Y, Ma L, et al. (2024): A blueprint for tumor-infiltrating B cells across human cancers. Science 384: eadj4857.
5.
Yang H, Zhang Z, Li J, et al. (2024): The dual role of B cells in the tumor microenvironment: implications for cancer immunology and therapy. Int J Mol Sci 25: 11825.
6.
Veh J, Ludwig C, Schrezenmeier H, Jahrsdörfer B (2024): Regulatory B cells-immunopathological and prognostic potential in humans. Cells 13: 357.
7.
Rodríguez-Zhurbenko N, Hernández AM (2024): The role of B-1 cells in cancer progression and anti-tumor immunity. Front Immunol 15: 1363176.
8.
Yang Y, Chen X, Pan J, et al. (2024): Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell S0092-8674(24)00712-8.
9.
Zhang E, Ding C, Li S, et al. (2023): Roles and mechanisms of tumor-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark Res 11: 28.
10.
Laumont CM, Banville AC, Gilardi M, et al. (2022): tumor-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer 22: 414-430.
11.
Binnewies M, Roberts EW, Kersten K, et al. (2018): Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24: 541-550.
12.
El-Tanani M, Rabbani SA, Babiker R, et al. (2024): Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Lett 591: 216894.
13.
Hladíková K, Koucký V, Bouček J, et al. (2019): Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J Immunother Cancer 7: 261.
14.
Wennhold K, Thelen M, Lehmann J, et al. (2021): CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol Res 9: 1098-1108.
15.
Garaud S, Buisseret L, Solinas C, et al. (2019): Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight 5: e129641.
16.
Leonard WJ, Lin JX, O’Shea JJ (2019): The (c) family of cytokines: Basic biology to therapeutic ramifications. Immunity 50: 832-850.
17.
Meylan M, Petitprez F, Becht E, et al. (2022): Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55: 527-541.e5.
18.
Rhodes DA, Isenberg DA (2017): TRIM21 and the function of antibodies inside cells. Trends Immunol 38: 916-926.
19.
Foss S, Bottermann M, Jonsson A, et al. (2019): TRIM21-from intracellular immunity to therapy. Front Immunol 10: 2049.
20.
Cabrita R, Lauss M, Sanna A, et al. (2020): Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577: 561-565.
21.
Cui C, Wang J, Fagerberg E, et al. (2021): Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184: 6101-18.e13.
22.
Lapointe R, Bellemare-Pelletier A, Housseau F, et al. (2003): CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63: 2836-2843.
23.
Wennhold K, Weber TM, Klein-Gonzalez N, et al. (2017): CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget 8: 27740-27753.
24.
Tao H, Lu L, Xia Y, et al. (2015): Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol 45: 999-1009.
25.
Xia Y, Tao H, Hu Y, et al. (2016): IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways. Oncotarget 7: 60461-60474.
26.
Biswas S, Mandal G, Payne KK, et al. (2021): IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591: 464-470.
27.
Baumgarth N (2016): B-1 cell heterogeneity and the regulation of natural and antigen-induced IgM production. Front Immunol 7: 324.
28.
Wu H, Xia L, Jia D, et al. (2020): PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis. Mol Immunol 119: 83-91.
29.
Xiao X, Lao XM, Chen MM, et al. (2016): PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov 6: 546-559.
30.
Wei X, Jin Y, Tian Y, et al. (2016): Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumor Biol 37: 6581-6588.
31.
Choi JK, Egwuagu CE (2021): Interleukin 35 regulatory B cells. J Mol Biol 433: 166607.
32.
Guerrero PA, McCarty JH (2017): TGF- activation and signaling in angiogenesis. InTech.
33.
Bao J, Betzler AC, Hess J, Brunner C (2023): Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma. Front Immunol 14: 1327795.
34.
Lu Y, Zhao Q, Liao JY, et al. (2020): Complement signals determine opposite effects of B cells in chemotherapy-induced immunity. Cell 180: 1081-1097.e24.
35.
Lykken JM, Candando KM, Tedder TF (2015): Regulatory B10 cell development and function. Int Immunol 27: 471-477.
36.
Jordakieva G, Bianchini R, Reichhold D, et al. (2021): IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. Oncoimmunology 10: 1880687.
37.
Bosisio FM, Wilmott JS, Volders N, et al. (2016): Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol 29: 347-358.
38.
Shalapour S, Lin XJ, Bastian IN, et al. (2017): Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551: 340-345.
39.
Lee KM, Stott RT, Zhao G, et al. (2014): TGF--producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol 44: 1728-1736.
40.
Kourko O, Seaver K, Odoardi N, et al. (2019): IL-27, IL-30, and IL-35: A cytokine triumvirate in cancer. Front Oncol 9: 969.
41.
Hollern DP, Xu N, Thennavan A, et al. (2019): B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179: 1191-206.e21.
42.
Zirakzadeh AA, Kinn J, Krantz D, et al. (2017): Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. Clin Immunol 176: 63-70.
43.
Morcrette G, Hirsch TZ, Badour E, et al. (2019): APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncoimmunology 8: e1583547.
44.
Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ (2021): STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer 9: e001906.
45.
Wu J, Chen L, Liu X, et al. (2015): Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Res Prev Treat 42: 1114-1118.
46.
Liang R, Li L, Wang Z (2021): Progress in clinical research on tumor-infiltrating lymphocytes in solid tumors. Chin J Clin Oncol 48: 1168-1172.
47.
Qin Y, Peng F, Ai L, et al. (2021): Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. Cancer Cell Int 21: 310.
48.
Harris RJ, Cheung A, Ng JCF, et al. (2021): Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer. Cancer Res 81: 4290-4304.
49.
Nelson MA, Ngamcherdtrakul W, Luoh SW, Yantasee W (2021): Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. Cancer Metastasis Rev 40: 519-536.
50.
Wang SS, Liu W, Ly D, et al. (2019): Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol 16: 6-18.
51.
Tokunaga R, Naseem M, Lo JH, et al. (2019): B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev 73: 10-19.
52.
Rodriguez AB, Peske JD, Woods AN, et al. (2021): Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep 36: 109422.
53.
Zheng M, Li YM, Liu ZY, et al. (2021): Prognostic landscape of tumor-infiltrating T and B cells in human cancer. Front Immunol 12: 731329.
54.
Zhao KL, Yang XJ, Jin HZ, et al. (2019): Double-edge role of B cells in tumor immunity: Potential molecular mechanism. Curr Med Sci 39: 685-689.
55.
Jing Y, Xu F, Liang W, et al. (2021): Role of regulatory B cells in gastric cancer: Latest evidence and therapeutics strategies. Int Immunopharmacol 96: 107581.
56.
Maibach F, Sadozai H, Seyed Jafari SM, et al. (2020): Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol 11: 2105.
57.
Hong C, Yao F (2022): Progress on tumor infiltrating lymphocytes in immunotherapy and prognosis evaluation of breast cancer. Cancer Res Prev Treat 49: 1180-1183.
58.
Zhang Z, Ma L, Goswami S, et al. (2019): Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology 8: e1571388.
59.
Hong H, He Y, Li Y, et al. (2024): Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology. J Transl Med 22: 1008.
60.
Garaud S, Dieu-Nosjean MC, Willard-Gallo K (2022): T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nat Commun 13: 2259.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
